Last reviewed · How we verify

NCT05872451: Current_ONB

Current Intensity for the Obturator Nerve Block

Completed NA Last updated 22 August 2024
What this trial tests

NA trial testing Rocuronium Bromide in Bladder Tumor in 30 participants. Completed in 15 April 2024.

Timeline
1 July 2023
Primary endpoint
15 April 2024
15 April 2024

Quick facts

Lead sponsorChosun University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment30
Start date1 July 2023
Primary completion15 April 2024
Estimated completion15 April 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Chosun University Hospital

Who can join

18 and older, any sex, with Bladder Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the present study was to find out the difference in current intensity required for nerve stimulation according to the presence or absence of neuromuscular blockade during the obturator nerve block procedure for TURP.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Adductor Muscle Contraction Under Deep Neuromuscular Blockade During TURBT Under General Anesthesia: Is Obturator Nerve Block Still Necessary?-A Prospective, Single-Arm, Exploratory Study.
    Cho SY, Jung KT. · · 2025 · cited 2× · PMID 40731836 · DOI 10.3390/medicina61071207

Verify or expand the search:

Other trials of Rocuronium Bromide

Trials testing the same drug.

Other recruiting trials for Bladder Tumor

Currently open trials in the same condition.

Other Chosun University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05872451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing